Immunotherapy of sepsis: flawed concept or faulty implementation? (Q33743647)

29 July 2017

1 reference

title

Immunotherapy of sepsis: flawed concept or faulty implementation? (English)

1 reference

29 July 2017

0 references

1 reference

Cross AS

1

1 reference

29 July 2017

Opal SM

2

1 reference

29 July 2017

Bhattacharjee AK

3

1 reference

29 July 2017

Donta ST

4

1 reference

29 July 2017

Peduzzi PN

5

1 reference

29 July 2017

Fürer E

6

1 reference

29 July 2017

Que JU

7

1 reference

29 July 2017

Cryz SJ

8

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

17 Suppl 2

1 reference

29 July 2017

S13-21

1 reference

Immunization against nosocomial infection

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Effects of IgM and IgG Antibody in Patients with Bacteremia Due to Gram-Negative Bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Preliminary Study on Treatment of Septic Shock Patients with Antilipopolysaccharide IgG from Blood Donors

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Antibodies to Lipopolysaccharides after Immunization of Humans with the Rough Mutant Escherichia coli J5

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

The human antibody response during natural bacteremic infection with gram-negative bacilli against lipopolysaccharide core determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Kinetics of interleukin-2 and interleukin-6 synthesis following major mechanical trauma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Stimulation of inflammatory markers after blunt trauma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Characterization of the human antibody response to an Escherichia coli O111:B4 (J5) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Serological characterisation of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

Anti-endotoxin antibodies directed against Escherichia coli R-1 oligosaccharide core-tetanus toxoid conjugate bind to smooth, live bacteria and smooth lipopolysaccharides and attenuate their tumor necrosis factor stimulating activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900230-3

7 January 2021

10.1016/S0264-410X(99)00230-3

Identifiers

DOI

1 reference

29 July 2017

1 reference